Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company Deals

Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors

Fineline Cube Aug 8, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a...

Policy / Regulatory

National Health Commission Unveils 10 Measures to Enhance Primary Healthcare Services

Fineline Cube Aug 8, 2023

The National Health Commission has issued a Notice outlining “Measures for Grassroots Health and Convenient...

Company Drug

Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae

Fineline Cube Aug 7, 2023

Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that...

Company Deals

ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China

Fineline Cube Aug 7, 2023

US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation...

Company Deals

Oramed Pharmaceuticals and Hefei Tianhui Biotech to Form Joint Venture for Oral Insulin Product

Fineline Cube Aug 7, 2023

Israel-based drug developer Oramed Pharmaceuticals Inc., (NASDAQ: ORMP) has revealed that a deal has been...

Company Drug

Astellas Pharma’s Izervay Receives FDA Approval for Geographic Atrophy Treatment

Fineline Cube Aug 7, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has announced that it has received new market approval...

Company

Regeneron Pharmaceuticals Halts Enrollment in REGN5678 Clinical Trial After Patient Deaths

Fineline Cube Aug 7, 2023

US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has reported in its Q2 2023 financial results the...

Company Drug

Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study

Fineline Cube Aug 7, 2023

China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US...

Company Medical Device

Jenscare Scientific and Lifetech Scientific Achieve Milestone with First Compassionate Use of LuX-Valve Plus

Fineline Cube Aug 7, 2023

Partners Jenscare Scientific Co., Ltd. (HKG: 9877), a leading structural heart disease device manufacturer based...

Policy / Regulatory

GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023

Fineline Cube Aug 7, 2023

The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking...

Company Medical Device

Venus Medtech Receives FDA IDE Approval for VenusP-Valve, a Milestone for Chinese Heart Valve Technology

Fineline Cube Aug 7, 2023

Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced obtaining Investigational Device Exemption (IDE) approval from...

Company Medical Device

MicroPort CardioFlow Announces Positive Results for Transcatheter Mitral Valve Replacement System

Fineline Cube Aug 7, 2023

China-based MicroPort Scientific Corp’s spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced positive...

Company Deals

Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation

Fineline Cube Aug 7, 2023

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...

Company Deals

Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China

Fineline Cube Aug 7, 2023

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...

Company

Gilead Sciences Inc. Reports 5% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based pharmaceutical major Gilead Sciences Inc., (NASDAQ: GILD) has released its financial results for the...

Company Legal / IP

Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second...

Company Legal / IP

GSK Files Patent Infringement Lawsuit Against Pfizer’s RSV Vaccine Abrysvo

Fineline Cube Aug 4, 2023

UK pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has taken US-based Pfizer Inc., (NYSE: PFE) to court,...

Company Deals

Novartis AG and Ionis Pharmaceuticals Renew Collaboration on Lp(a)-Driven CVD Drug

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has returned to US-based Ionis Pharmaceuticals Inc., (NASDAQ:...

Company Drug

Grand Pharmaceutical Group Gets NMPA Approval for Generic Eplerenone for Hypertension

Fineline Cube Aug 4, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal

Fineline Cube Aug 4, 2023

China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...

Posts pagination

1 … 473 474 475 … 647

Recent updates

  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
  • Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
  • Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
  • Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.